Quanterix(US:QTRX)2025-11-10 21:08Financial Performance - Revenue for Q3 2025 was $40.2 million, a 12.3% increase from $35.8 million in Q3 2024[7] - The net loss for Q3 2025 was $33.5 million, compared to a net loss of $8.4 million in Q3 2024[12] - For the three months ended September 30, 2025, the net loss was $33.517 million, compared to a net loss of $8.353 million for the same period in 2024[22] - Total revenues for the three months ended September 30, 2025, were $40.233 million, an increase from $35.813 million in the same period of 2024[22] - The company reported total operating expenses of $54.531 million for the three months ended September 30, 2025, compared to $31.901 million in 2024[28] Margins and Profitability - GAAP gross margin decreased to 42.8% from 56.3% in the prior year, while adjusted gross margin was 45.9%, down from 50.7%[7] - Adjusted EBITDA loss was $11.9 million, compared to a loss of $5.5 million in the prior year, primarily due to higher acquisition and restructuring charges[7] - Adjusted EBITDA for the three months ended September 30, 2025, was $(11.885) million, with an adjusted EBITDA margin of (29.5)%, compared to $(5.470) million and (15.3)% in 2024[22] - Adjusted gross profit for the three months ended September 30, 2025, was $18.468 million, with an adjusted gross margin of 45.9%, compared to $18.142 million and 50.7% in 2024[28] Cash Flow and Guidance - The company ended Q3 2025 with $138.1 million in cash and equivalents, with adjusted cash usage of $16.1 million expected to decline in Q4 2025[7] - Quanterix expects adjusted cash usage for 2025 to be approximately $34 to $38 million, aiming for cash flow breakeven in 2026[8] - Adjusted cash usage for the three months ended September 30, 2025, was $(16.063) million, compared to $(3.330) million in the same period of 2024[25] Strategic Initiatives - Quanterix is reiterating its 2025 revenue guidance of $130 to $135 million, with pro forma revenue expected to be between $165 and $170 million assuming full-year performance from Akoya[6] - The company achieved $67 million in cost synergies from the Akoya integration, consolidating sales organizations and manufacturing facilities[7] - Quanterix launched eight new Simoa assays in the first nine months of 2025 and established new partnerships in the Asia-Pacific region[7] - The company anticipates potential benefits from the acquisition of Akoya Biosciences Inc. and the launch of its next-generation instrument, Simoa One[31] Risks and Challenges - The company is facing risks related to the integration of its business with Akoya and the realization of expected benefits from recent acquisitions[31] - The company reported a significant increase in impairment and restructuring costs, totaling $7.174 million for the three months ended September 30, 2025[28] - The company incurred acquisition and integration related costs of $7.315 million for the three months ended September 30, 2025[21]